Last reviewed · How we verify
Betaxolol eye drops
Betaxolol is a selective beta-1 adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.
Betaxolol is a selective beta-1 adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Betaxolol eye drops |
|---|---|
| Sponsor | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. |
| Drug class | Selective beta-1 adrenergic antagonist (beta-blocker) |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Betaxolol selectively blocks beta-1 adrenergic receptors on the ciliary body epithelium, which reduces the production and secretion of aqueous humor. This leads to a decrease in intraocular pressure, making it effective for treating glaucoma and ocular hypertension. As an eye drop formulation, it provides local ocular effects with minimal systemic absorption.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular irritation or discomfort
- Blurred vision
- Conjunctival hyperemia
- Tearing
- Systemic beta-blocker effects (rare with topical use)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betaxolol eye drops CI brief — competitive landscape report
- Betaxolol eye drops updates RSS · CI watch RSS
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. portfolio CI